Metagenomi (NASDAQ:MGX) Given Buy Rating at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Metagenomi (NASDAQ:MGX) in a research report released on Thursday morning,Benzinga reports. They currently have a $7.00 price target on the stock.

Other equities analysts have also issued reports about the company. Chardan Capital reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Metagenomi in a research note on Wednesday, November 20th. BMO Capital Markets reduced their price target on shares of Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $15.50.

Metagenomi Trading Up 3.8 %

Shares of Metagenomi stock opened at $1.89 on Thursday. The business’s fifty day moving average price is $2.06 and its 200 day moving average price is $3.69. Metagenomi has a twelve month low of $1.61 and a twelve month high of $12.74.

Hedge Funds Weigh In On Metagenomi

A number of institutional investors have recently added to or reduced their stakes in MGX. Rhumbline Advisers acquired a new position in shares of Metagenomi in the 2nd quarter valued at approximately $26,000. BNP Paribas Financial Markets increased its stake in shares of Metagenomi by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after buying an additional 7,256 shares during the last quarter. Virtu Financial LLC acquired a new stake in Metagenomi in the third quarter valued at $33,000. XTX Topco Ltd bought a new position in Metagenomi during the 2nd quarter valued at $66,000. Finally, Green Alpha Advisors LLC acquired a new position in Metagenomi during the 3rd quarter worth $69,000.

About Metagenomi

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.